Abstract
Several cell populations derived from bone marrow (BM) have been shown to possess cardiac regenerative potential. Among these are freshly isolated CD133+ hematopoietic as well as culture-expanded mesenchymal stem cells. Alternatively, by purifying CD271+ cells from BM, mesenchymal progenitors can be enriched without an ex vivo cultivation. With regard to the limited available number of freshly isolated BM-derived stem cells, the effect of the dosage on the therapeutic efficiency is of particular interest. Therefore, in the present pre-clinical study, we investigated human BM-derived CD133+ and CD271+ stem cells for their cardiac regenerative potential three weeks post-myocardial infarction (MI) in a dose-dependent manner. The improvement of the hemodynamic function as well as cardiac remodeling showed no therapeutic difference after the transplantation of both 100,000 and 500,000 stem cells. Therefore, beneficial stem cell transplantation post-MI is widely independent of the cell dose and detrimental stem cell amplification in vitro can likely be avoided.
Highlights
The treatment with stem or progenitor cells offers a potential chance of true regeneration and regrowth of irreversibly damaged tissue as well as anti-inflammatory effects
Intramyocardial stem cell transplantation has been investigated as a novel therapy option since Asahara and coworkers first found evidence of bone marrow (BM) cell participation in cardiac healing [1]
The question a dose-response dose‐response relationship plays a central role in the clinical application of these stem cell relationship plays a central role in the clinical application of these stem cell populations
Summary
The treatment with stem or progenitor cells offers a potential chance of true regeneration and regrowth of irreversibly damaged tissue as well as anti-inflammatory effects. Intramyocardial stem cell transplantation has been investigated as a novel therapy option since Asahara and coworkers first found evidence of bone marrow (BM) cell participation in cardiac healing [1]. As well as clinical trials, have been conducted using widely mixed cell populations such as total nucleated or mononuclear BM-derived cells as well as purified cells of specific cell types [2,3,4]. No single most effective cell type has been identified yet. Hematopoietic stem cells (HSC) as well as mesenchymal stem cells (MSC) have been studied in the most detail [2,5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
